Pre-made Abelacimab benchmark antibody ( Whole mAb, anti-F11/F11 mRNA therapeutic antibody, Anti-FXI/PTA Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Abelacimab biosimilar, Whole mAb, Anti-F11 Antibody: Anti-FXI/PTA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Abelacimab (previously known as MAA 868) is a fully human, factor XI monoclonal antibody, being developed by Anthos Therapeutics under the license from Novartis, for the prevention of cardiovascular disorders including stroke due to thrombosis and thromboembolism in patients with atrial fibrillation.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-002-1mg	1mg	3090
GMP-Bios-ab-002-10mg	10mg	Inquiry
GMP-Bios-ab-002-100mg	100mg	Inquiry
GMP-Bios-ab-002-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Abelacimab biosimilar, Whole mAb, Anti-F11 Antibody: Anti-FXI/PTA therapeutic antibody
INN Name	Abelacimab
Target	F11 mRNA
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	6r8x:CB
Year Proposed	2018
Year Recommended	2019
Companies	Novartis
Conditions Approved	na
Conditions Active	Venous Thromboembolism; Stroke;Thrombosis
Conditions Discontinued	na
Development Tech	na